Peptide Synthesis Market
完整報告名稱與涵蓋範圍
Peptide Synthesis Market by Instruments (Synthesizers, Purification, Lyophilizers, Analytical), Reagents (Amino Acids, Resins), Technique (Chemical, Biological), Services (Custom Synthesis, Modification), Application, End User - Global Forecast to 2031
報告摘要
The global peptide synthesis market is estimated to reach USD 1.54 billion by 2031 from USD 0.98 billion in 2026, at a CAGR of 9.5% from 2026 to 2031. The market is projected to grow steadily over the forecast period, driven by the expanding pipeline of peptide-based therapeutics, rising demand for GLP-1 and other metabolic peptides, and broader use of synthetic peptides in oncology, diagnostics, and research. Growth is further supported by advances in automated solid-phase peptide synthesis, high-throughput platforms, specialized modification chemistries, and peptide purification and analytical technologies. However, high material and solvent consumption, synthesis complexity for long and difficult sequences, purification challenges, and the need for specialized technical expertise are expected to restrain broader market growth.
“The custom peptide synthesis services segment accounted for the largest share, by service type, in 2025.”
Based on service type, the peptide synthesis services market is segmented into custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, and peptide library preparation/synthesis services. In 2025, custom peptide synthesis services accounted for the largest market share, driven by growing outsourcing of standard, high-purity, modified, long, and complex peptide requirements. These services are widely used across drug discovery, therapeutic development, diagnostic research, antibody generation, and academic research workflows. Demand is further supported by increasing requirements for rapid turnaround, customized purity levels, difficult sequences, and specialized peptide formats. Their broad applicability across pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes continues to support the segment’s leading position globally.
“Chemical synthesis segment accounted for the largest share of the peptide synthesis products market, by technique, in 2025.”
Based on technique, the peptide synthesis products market is segmented into chemical synthesis and biological synthesis. Chemical synthesis accounted for the largest market share in 2025, due to the widespread use of solid-phase peptide synthesis (SPPS) for research and therapeutic peptide production. SPPS offers established Fmoc- and Boc-based chemistries, compatibility with automation, sequence flexibility, and a broad ecosystem of synthesizers, resins, protected amino acids, and coupling reagents. Liquid-phase synthesis, hybrid approaches, and chemical ligation methods complement SPPS for selected fragments and complex sequences. The maturity of chemical synthesis workflows and their extensive use across pharmaceutical, biotechnology, CRO, and academic laboratories continue to support the segment’s leading position.
“Asia Pacific is expected to register the highest CAGR in the peptide synthesis market from 2026 to 2031.”
The peptide synthesis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to grow at the highest CAGR during the forecast period, driven by expanding pharmaceutical and biotechnology R&D, growing peptide drug development, rising outsourcing of custom peptide synthesis, and improvements in research infrastructure. Growth is further supported by increasing adoption of automated peptide synthesizers, advanced purification and analytical platforms, and expanding demand for peptide therapeutics across China, India, Japan, South Korea, and Australia. Established regional suppliers and expanding global life-science operations continue to strengthen peptide synthesis capabilities across the region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side (80%) and Demand Side (20%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), Kaneka Corporation (Japan), Biotage AB (Sweden), Sartorius AG (Germany), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), GL Biochem (Shanghai) Ltd. (China), Mesa Laboratories, Inc. (US), Danaher Corporation (US), Chem-Impex International, Inc. (US), Advanced ChemTech (ACT) (US), Mimotopes Pty Ltd (Australia), Iris Biotech GmbH (Germany), AAPPTec, LLC (US), Enamine Ltd. (Ukraine), Intavis Peptide Services (Germany), JPT Peptide Technologies GmbH (Germany), Innovagen AB (Sweden), Peptide Protein Research Ltd. (UK), LifeTein LLC (US), Creative Peptides (US), Genemed Synthesis, Inc. (US), ChinaPeptides Co., Ltd. (China), and Beijing Scilight Biotechnology Co., Ltd. (China) are some of the key companies offering peptide synthesis products and services.
Research Coverage
This research report categorizes the peptide synthesis market by offering (products, services), product type (instruments, reagents & consumables), technique (chemical synthesis, biological synthesis), service type (custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, peptide library preparation/synthesis services), application (therapeutic applications, diagnostics applications, research applications), product end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), service end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the peptide synthesis market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product & services portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the peptide synthesis market.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the peptide synthesis market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies:
The report provides insights on the following pointers:
• Analysis of key drivers (surging demand for GLP-1 and other high-volume peptide therapeutics, rising complexity of peptide modalities requiring advanced synthesis and purification, expanding peptide drug pipelines and clinical development activity), restraints (high material consumption and waste generation in large-scale peptide synthesis, high cost and supply sensitivity of GMP-grade synthesis inputs), opportunities (rapid expansion of global GMP peptide manufacturing capacity, shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies), and challenges (maintaining yield, purity, and batch consistency for complex peptides at scale) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products & services of the peptide synthesis market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the peptide synthesis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), Kaneka Corporation (Japan), Biotage AB (Sweden), Sartorius AG (Germany), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), GL Biochem (Shanghai) Ltd. (China), Mesa Laboratories, Inc. (US), Danaher Corporation (US), Chem-Impex International, Inc. (US), Advanced ChemTech (ACT) (US), Mimotopes Pty Ltd (Australia), Iris Biotech GmbH (Germany), AAPPTec, LLC (US), Enamine Ltd. (Ukraine), Intavis Peptide Services (Germany), JPT Peptide Technologies GmbH (Germany), Innovagen AB (Sweden), Peptide Protein Research Ltd. (UK), LifeTein LLC (US), Creative Peptides (US), Genemed Synthesis, Inc. (US), ChinaPeptides Co., Ltd. (China), and Beijing Scilight Biotechnology Co., Ltd. (China).
The report also helps stakeholders understand trends in the peptide synthesis market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product & services launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand/product/service comparisons, vendor evaluations, and financial metrics of the peptide synthesis sector.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 59
1.1 STUDY OBJECTIVES 59
1.2 MARKET DEFINITION 59
1.3 STUDY SCOPE 59
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 60
1.3.2 INCLUSIONS & EXCLUSIONS 61
1.3.3 YEARS CONSIDERED 63
1.3.4 CURRENCY CONSIDERED 63
1.4 STAKEHOLDERS 63
1.5 SUMMARY OF CHANGES 64
2 EXECUTIVE SUMMARY 65
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 65
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 67
2.3 DISRUPTIVE TRENDS IN PEPTIDE SYNTHESIS MARKET 68
2.4 HIGH-GROWTH SEGMENTS 69
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 70
3 PREMIUM INSIGHTS 71
3.1 PEPTIDE SYNTHESIS MARKET OVERVIEW 71
3.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING 72
3.3 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 73
3.4 PEPTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2026 VS. 2031 (%) 74
4 MARKET OVERVIEW 75
4.1 INTRODUCTION 75
4.2 MARKET DYNAMICS 75
4.2.1 DRIVERS 76
4.2.1.1 Surging demand for GLP-1 and other high-volume peptide therapeutics 76
4.2.1.2 Rising complexity of peptide modalities requiring advanced synthesis and purification 77
4.2.1.3 Expanding peptide drug pipelines and clinical development activity 77
4.2.2 RESTRAINTS 78
4.2.2.1 High material consumption and waste generation in large-scale solid-phase peptide synthesis 78
4.2.2.2 High cost and supply sensitivity of GMP-grade synthesis inputs 79
4.2.3 OPPORTUNITIES 79
4.2.3.1 Rapid expansion of global GMP peptide manufacturing capacity 79
4.2.3.2 Shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies 79
4.2.4 CHALLENGES 80
4.2.4.1 Maintaining yield, purity, and batch consistency for complex peptides at scale 80
4.3 UNMET NEEDS & WHITE SPACES 80
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 81
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 82
5 INDUSTRY TRENDS 83
5.1 PORTER’S FIVE FORCES ANALYSIS 83
5.1.1 THREAT OF NEW ENTRANTS 84
5.1.2 THREAT OF SUBSTITUTES 84
5.1.3 BARGAINING POWER OF BUYERS 84
5.1.4 BARGAINING POWER OF SUPPLIERS 84
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 84
5.2 MACROECONOMIC OUTLOOK 85
5.2.1 INTRODUCTION 85
5.2.2 GDP TRENDS & FORECAST 85
5.2.3 TRENDS IN GLOBAL PEPTIDE SYNTHESIS MARKET 86
5.3 VALUE CHAIN ANALYSIS 86
5.4 ECOSYSTEM ANALYSIS 88
5.5 PRICING ANALYSIS 90
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 91
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION 92
5.6 TRADE ANALYSIS 93
5.6.1 IMPORT SCENARIO (HS CODE 902720) 93
5.6.2 EXPORT SCENARIO (HS CODE 902720) 95
5.6.3 IMPORT SCENARIO (HS CODE 841933) 96
5.6.4 EXPORT SCENARIO (HS CODE 841933) 97
5.7 KEY CONFERENCES & EVENTS, 2026–2027 99
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
5.9 INVESTMENT & FUNDING ACTIVITY 100
5.10 IMPACT OF 2025 US TARIFFS ON PEPTIDE SYNTHESIS MARKET 101
5.10.1 INTRODUCTION 101
5.10.2 PRICE IMPACT ANALYSIS 101
5.10.3 IMPACT ON COUNTRY/REGION 102
5.10.3.1 North America 102
5.10.3.2 Europe 102
5.10.3.3 Asia Pacific 103
5.10.4 IMPACT ON END-USE INDUSTRIES 103
5.10.4.1 Pharmaceutical & biotechnology companies 103
5.10.4.2 CROs & CDMOs 104
5.10.4.3 Academic & research institutes, diagnostic labs, and other end users 104
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 105
6.1 TECHNOLOGY ANALYSIS 105
6.1.1 KEY EMERGING TECHNOLOGIES 105
6.1.1.1 Solid-phase peptide synthesis (SPPS) 105
6.1.1.2 Liquid-phase peptide synthesis (LPPS) 106
6.1.1.3 Enzymatic peptide synthesis 106
6.1.1.4 Recombinant peptide synthesis 106
6.1.1.5 Continuous-flow peptide synthesis 107
6.1.2 COMPLEMENTARY TECHNOLOGIES 107
6.1.2.1 Analytical characterization & quality-control technologies 107
6.1.2.2 Purification & downstream processing technologies 107
6.1.2.3 Peptide ligation technologies 108
6.1.3 ADJACENT TECHNOLOGIES 108
6.1.3.1 Protein design & engineering 108
6.1.3.2 Synthetic biology/genetic-code engineering 108
6.2 TECHNOLOGY/PRODUCT ROADMAP 109
6.3 PATENT ANALYSIS 109
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS 110
6.4 FUTURE APPLICATIONS 113
6.5 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET 113
6.5.1 BEST PRACTICES IN PEPTIDE SYNTHESIS WORKFLOW 114
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET 115
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 115
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE
SYNTHESIS MARKET 115
7 SUSTAINABILITY & REGULATORY LANDSCAPE 117
7.1 REGIONAL REGULATIONS & COMPLIANCE 117
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
7.1.2 REGULATORY FRAMEWORK 120
7.1.3 INDUSTRY STANDARDS 121
7.2 SUSTAINABILITY INITIATIVES 121
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 122
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 123
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 124
8.1 DECISION-MAKING PROCESS 124
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 125
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 125
8.2.2 KEY BUYING CRITERIA, BY END USER 125
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 127
8.4 UNMET NEEDS FROM END USERS 127
8.5 MARKET PROFITABILITY 128
9 PEPTIDE SYNTHESIS MARKET, BY OFFERING 129
9.1 INTRODUCTION 130
9.2 PRODUCTS 130
9.2.1 IN-HOUSE WORKFLOW CONTROL AND RECURRING PEPTIDE-SPECIFIC DEMAND TO DRIVE MARKET GROWTH 130
9.3 SERVICES 134
9.3.1 GROWING OUTSOURCING OF COMPLEX AND VARIABLE-VOLUME PEPTIDE PROJECTS TO SUPPORT MARKET GROWTH 134
10 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE 138
10.1 INTRODUCTION 139
10.2 REAGENTS & CONSUMABLES 139
10.2.1 REAGENTS 143
10.2.1.1 Amino acid building blocks 147
10.2.1.1.1 Expanding use of protected and non-natural residues to drive demand for amino acid building blocks 147
10.2.1.2 Resins 151
10.2.1.2.1 Broader linker chemistry and high-throughput SPPS formats to support steady resin demand 151
10.2.1.3 Coupling reagents 154
10.2.1.3.1 Need for faster activation and lower side-reaction risk to sustain demand for advanced coupling chemistry 154
10.2.1.4 Peptide modification reagents 158
10.2.1.4.1 Half-life extension, targeting, and conjugation strategies to make modification reagents fastest-growing reagent category 158
10.2.1.5 Labeling reagents 161
10.2.1.5.1 Rising use of labeled peptides in imaging, diagnostics, binding studies, and assay development to expand demand 161
10.2.1.6 Protection & deprotection reagents 165
10.2.1.6.1 Orthogonal protecting strategies and pressure to reduce hazardous chemistry to shape product selection 165
10.2.1.7 Cleavage reagents 168
10.2.1.7.1 Continued SPPS use and demand for cleaner cleavage profiles to support recurring cleavage-chemistry purchases 168
10.2.1.8 Other reagents 172
10.2.2 CONSUMABLES 175
10.2.2.1 Higher synthesis throughput and purification workload to support steady recurring consumables demand 175
10.3 INSTRUMENTS 178
10.3.1 PEPTIDE SYNTHESIZERS 183
10.3.1.1 Peptide synthesizers, by type 188
10.3.1.1.1 Automated peptide synthesizers 188
10.3.1.1.2 Manual peptide synthesizers 192
10.3.1.2 Peptide synthesizers, by technology 195
10.3.1.2.1 Conventional-batch peptide synthesizers 195
10.3.1.2.2 Microwave-assisted peptide synthesizers 199
10.3.1.2.3 Hybrid peptide synthesizers 203
10.3.1.2.4 Other peptide synthesizers 206
10.3.2 PURIFICATION SYSTEMS 210
10.3.2.1 Higher crude-peptide complexity and throughput bottlenecks to increase demand for scalable purification platforms 210
10.3.3 ANALYTICAL & QUALITY CONTROL INSTRUMENTS 213
10.3.3.1 Impurity profiling, identity confirmation, and tighter peptide quality requirements to sustain analytical platform investment 213
10.3.4 LYOPHILIZATION EQUIPMENT 217
10.3.4.1 Need for stable dry peptide formats and scale-appropriate freeze-drying capacity to support demand 217
10.3.5 OTHER INSTRUMENTS 220
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE 224
11.1 INTRODUCTION 225
11.2 CHEMICAL SYNTHESIS 225
11.2.1 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) 229
11.2.1.1 Automation, rapid iterative chemistry, and commercial-scale familiarity to sustain SPPS as largest chemical synthesis method 229
11.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) 233
11.2.2.1 Solvent-efficiency improvements and large-scale economics to make LPPS fastest-growing chemical synthesis method 233
11.2.3 OTHER CHEMICAL METHODS 236
11.3 BIOLOGICAL SYNTHESIS 240
11.3.1 RECOMBINANT PEPTIDE PRODUCTION 244
11.3.1.1 Scalable microbial expression and established biologics infrastructure to keep recombinant production dominant within biological synthesis 244
11.3.2 ENZYMATIC PEPTIDE SYNTHESIS 247
11.3.2.1 High selectivity and lower-solvent ligation to position enzymatic synthesis as fastest-growing biological method 247
12 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER 251
12.1 INTRODUCTION 252
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 252
12.2.1 EXPANDING PEPTIDE PIPELINES AND IN-HOUSE MANUFACTURING CAPABILITIES TO DRIVE MARKET GROWTH 252
12.3 CROS & CDMOS 256
12.3.1 RAPID OUTSOURCING AND CAPACITY EXPANSION TO MAKE CROS & CDMOS FASTEST-GROWING PRODUCT END-USER CATEGORY 256
12.4 ACADEMIC & RESEARCH INSTITUTES 259
12.4.1 DISCOVERY-LED PEPTIDE LIBRARIES AND GREATER ACCESS TO AUTOMATED BENCHTOP SYSTEMS TO SUSTAIN RESEARCH INSTITUTE DEMAND 259
12.5 MEDICAL DEVICE COMPANIES 263
12.5.1 PEPTIDE-FUNCTIONALIZED BIOSENSORS AND SURFACE-ENGINEERED DEVICES TO BROADEN SPECIALIZED DEMAND FOR MODIFIED SYNTHESIS PRODUCTS 263
12.6 CLINICAL & DIAGNOSTIC LABORATORIES 266
12.6.1 HIGHER ASSAY SPECIFICITY AND STANDARDIZED PEPTIDE REAGENTS TO SUPPORT ADOPTION IN CLINICAL AND DIAGNOSTIC LABORATORIES 266
13 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE 270
13.1 INTRODUCTION 271
13.2 CUSTOM PEPTIDE SYNTHESIS SERVICES 271
13.2.1 FLEXIBLE SEQUENCE, PURITY, AND QUANTITY REQUIREMENTS TO KEEP CUSTOM PEPTIDE SYNTHESIS SERVICES LARGEST SERVICE CATEGORY 271
13.3 PEPTIDE ENGINEERING & MODIFICATION SERVICES 275
13.3.1 GROWING NEED FOR HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION TO MAKE ENGINEERING & MODIFICATION SERVICES FASTEST-GROWING CATEGORY 275
13.4 PEPTIDE PURIFICATION SERVICES 278
13.4.1 MORE DIFFICULT PEPTIDE SEQUENCES AND TIGHTER PURITY SPECIFICATIONS TO SUSTAIN DEMAND FOR OUTSOURCED PURIFICATION 278
13.5 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES 282
13.5.1 RISING MOLECULAR COMPLEXITY AND QUALITY EXPECTATIONS TO EXPAND PEPTIDE ANALYTICAL & CHARACTERIZATION OUTSOURCING 282
13.6 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES 285
13.6.1 HIGH-THROUGHPUT SCREENING AND IMMUNE-MONITORING WORKFLOWS TO INCREASE ADOPTION OF PEPTIDE LIBRARY SERVICES 285
14 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER 289
14.1 INTRODUCTION 290
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 290
14.2.1 BROAD OUTSOURCING ACROSS DISCOVERY AND DEVELOPMENT TO BOOST MARKET GROWTH 290
14.3 CROS & CDMOS 294
14.3.1 EXTERNAL CAPACITY, SPECIALIZED CHEMISTRY, AND NETWORK FLEXIBILITY TO MAKE CROS & CDMOS FASTEST-GROWING SERVICE END-USER CATEGORY 294
14.4 ACADEMIC & RESEARCH INSTITUTES 297
14.4.1 FLEXIBLE PROJECT-SCALE OUTSOURCING AND SPECIALIZED PEPTIDE FORMATS TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES 297
14.5 MEDICAL DEVICE COMPANIES 301
14.5.1 PEPTIDE-FUNCTIONALIZED DEVICES AND BIOSENSORS TO INCREASE DEMAND FOR SPECIALIZED SYNTHESIS, MODIFICATION, AND CONJUGATION SERVICES 301
14.6 CLINICAL & DIAGNOSTIC LABORATORIES 304
14.6.1 ASSAY STANDARDIZATION AND CLINICAL-GRADE QUALITY REQUIREMENTS TO SUPPORT OUTSOURCED PEPTIDE SERVICES FOR DIAGNOSTIC LABORATORIES 304
15 PEPTIDE SYNTHESIS MARKET, BY APPLICATION 308
15.1 INTRODUCTION 309
15.2 THERAPEUTIC APPLICATIONS 309
15.2.1 THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION 313
15.2.1.1 Diabetes 313
15.2.1.1.1 Large established peptide classes and sustained need for high-purity analogs drive growth 313
15.2.1.2 Obesity 317
15.2.1.2.1 Late-stage dual- and triple-agonist pipelines and rapid commercial scale-up to make obesity fastest-growing therapeutic indication 317
15.2.1.3 Cancer 320
15.2.1.3.1 Targeted delivery, neoantigen programs, and radioligand development to deepen peptide-synthesis requirements in oncology 320
15.2.1.4 Autoimmune disease 324
15.2.1.4.1 Targeted oral peptides and antigen-specific immunomodulation to broaden peptide use in chronic autoimmune disorders 324
15.2.1.5 Other therapeutic indications 327
15.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE 331
15.2.2.1 Metabolic & hormonal peptides 331
15.2.2.1.1 High-volume incretin, insulin, and hormone-peptide demand to drive market growth 331
15.2.2.2 Peptide inhibitors 335
15.2.2.2.1 Improved oral delivery, structural constraint, and access to difficult protein interfaces to expand peptide inhibitor development 335
15.2.2.3 Peptide-drug conjugates (PDCs) 338
15.2.2.3.1 Targeted payload delivery and radioconjugate pipelines to make PDCs fastest-growing therapeutic molecule category 338
15.2.2.4 Peptide-based vaccines 342
15.2.2.4.1 Neoepitope discovery, immune monitoring, and personalized vaccine strategies to support high-diversity peptide synthesis demand 342
15.2.2.5 Other therapeutic modalities 345
15.3 RESEARCH APPLICATIONS 349
15.3.1 HIGH-THROUGHPUT DISCOVERY, BIOMARKER STUDIES, AND RECURRING CUSTOM-PEPTIDE USE TO SUSTAIN BROAD RESEARCH DEMAND BASE 349
15.4 DIAGNOSTIC APPLICATIONS 352
15.4.1 PEPTIDE-BASED ASSAY REAGENTS, IMAGING LIGANDS, AND COMPANION-DIAGNOSTIC DEVELOPMENT TO EXPAND SPECIALIZED DIAGNOSTIC DEMAND 352
16 PEPTIDE SYNTHESIS MARKET, BY REGION 356
16.1 INTRODUCTION 357
16.2 NORTH AMERICA 357
16.2.1 US 365
16.2.1.1 Dense peptide pipelines and domestic capacity to sustain market growth 365
16.2.2 CANADA 372
16.2.2.1 Biopharma manufacturing investment and research demand to support steady expansion 372
16.3 EUROPE 378
16.3.1 GERMANY 385
16.3.1.1 Integrated peptide manufacturing and strong chemical supply chains to support demand 385
16.3.2 UK 392
16.3.2.1 Research intensity and diagnostic peptide capability to support specialized demand 392
16.3.3 FRANCE 399
16.3.3.1 Expanding SPPS capacity to strengthen commercial peptide supply base 399
16.3.4 ITALY 405
16.3.4.1 Injectable manufacturing integration to support peptide development-to-product workflows 405
16.3.5 SPAIN 412
16.3.5.1 Research and specialty-pharma activity to sustain demand for imported synthesis solutions 412
16.3.6 REST OF EUROPE 418
16.4 ASIA PACIFIC 425
16.4.1 CHINA 435
16.4.1.1 Large-scale TIDES capacity and domestic supplier depth to accelerate market expansion 435
16.4.2 JAPAN 441
16.4.2.1 Advanced drug discovery and specialty peptide innovation to sustain high-value demand 441
16.4.3 INDIA 448
16.4.3.1 Cost-efficient CRDMO expansion and new peptide capacity to accelerate market growth 448
16.4.4 SOUTH KOREA 455
16.4.4.1 Biotech investment and long-acting peptide development to expand specialized demand 455
16.4.5 AUSTRALIA 462
16.4.5.1 Research-intensive institutions and biotech pipelines to sustain high-value peptide demand 462
16.4.6 REST OF ASIA PACIFIC 469
16.5 LATIN AMERICA 476
16.5.1 BRAZIL 484
16.5.1.1 Large research base and metabolic-disease focus to make Brazil core Latin American market 484
16.5.2 MEXICO 491
16.5.2.1 US-linked manufacturing and clinical research to support peptide synthesis demand 491
16.5.3 REST OF LATIN AMERICA 498
16.6 MIDDLE EAST 505
16.6.1 GCC COUNTRIES 513
16.6.1.1 Saudi Arabia 520
16.6.1.1.1 Localization initiatives and research funding to support rising peptide workflow adoption 520
16.6.1.2 UAE 527
16.6.1.2.1 Biotech hubs and regional distribution to strengthen access to peptide synthesis solutions 527
16.6.1.3 Rest of GCC Countries 534
16.6.2 REST OF MIDDLE EAST 541
16.7 AFRICA 548
16.7.1 RESEARCH-LED DEMAND AND IMPORT DEPENDENCE TO SHAPE MARKET 548
17 COMPETITIVE LANDSCAPE 556
17.1 OVERVIEW 556
17.2 KEY PLAYER STRATEGY/RIGHT TO WIN 556
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET 557
17.3 REVENUE ANALYSIS, 2021–2025 558
17.4 MARKET SHARE ANALYSIS, 2025 559
17.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025 561
17.5.1 STARS 561
17.5.2 EMERGING LEADERS 562
17.5.3 PERVASIVE PLAYERS 562
17.5.4 PARTICIPANTS 562
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 564
17.5.5.1 Company footprint 564
17.5.5.2 Region footprint 565
17.5.5.3 Offering footprint 566
17.5.5.4 Product type footprint 567
17.5.5.5 Application footprint 568
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 569
17.6.1 PROGRESSIVE COMPANIES 569
17.6.2 RESPONSIVE COMPANIES 569
17.6.3 DYNAMIC COMPANIES 569
17.6.4 STARTING BLOCKS 569
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 571
17.6.5.1 Detailed list of key startups/SMEs 571
17.6.5.2 Competitive benchmarking of key startups/SMEs 572
17.7 COMPANY VALUATION & FINANCIAL METRICS 573
17.7.1 FINANCIAL METRICS 573
17.7.2 COMPANY VALUATION 573
17.8 PRODUCT/SERVICE COMPARISON 574
17.9 COMPETITIVE SCENARIO 575
17.9.1 PRODUCT LAUNCHES 575
17.9.2 DEALS 576
17.9.3 EXPANSIONS 576
18 COMPANY PROFILES 577
18.1 KEY PLAYERS 577
18.1.1 THERMO FISHER SCIENTIFIC INC. 577
18.1.1.1 Business overview 577
18.1.1.2 Products & services offered 578
18.1.1.3 Recent developments 580
18.1.1.3.1 Product launches 580
18.1.1.3.2 Deals 581
18.1.1.3.3 Expansions 581
18.1.1.4 MnM view 581
18.1.1.4.1 Right to win 581
18.1.1.4.2 Strategic choices 582
18.1.1.4.3 Weaknesses & competitive threats 582
18.1.2 MERCK KGAA 583
18.1.2.1 Business overview 583
18.1.2.2 Products & services offered 584
18.1.2.3 Recent developments 586
18.1.2.3.1 Deals 586
18.1.2.3.2 Expansions 586
18.1.2.4 MnM view 587
18.1.2.4.1 Right to win 587
18.1.2.4.2 Strategic choices 587
18.1.2.4.3 Weaknesses & competitive threats 587
18.1.3 AGILENT TECHNOLOGIES, INC. 588
18.1.3.1 Business overview 588
18.1.3.2 Products & services offered 589
18.1.3.3 Recent developments 590
18.1.3.3.1 Product launches 590
18.1.3.4 MnM view 591
18.1.3.4.1 Right to win 591
18.1.3.4.2 Strategic choices 591
18.1.3.4.3 Weaknesses and competitive threats 591
18.1.4 GENSCRIPT BIOTECH CORPORATION 592
18.1.4.1 Business overview 592
18.1.4.2 Products & services offered 594
18.1.4.3 Recent developments 595
18.1.4.3.1 Expansions 595
18.1.4.4 MnM view 595
18.1.4.4.1 Right to win 595
18.1.4.4.2 Strategic choices 595
18.1.4.4.3 Weaknesses & competitive threats 595
18.1.5 KANEKA CORPORATION 596
18.1.5.1 Business overview 596
18.1.5.2 Products & services offered 597
18.1.5.3 Recent developments 599
18.1.5.3.1 Expansions 599
18.1.5.4 MnM view 599
18.1.5.4.1 Right to win 599
18.1.5.4.2 Strategic choices 599
18.1.5.4.3 Weaknesses & competitive threats 599
18.1.6 SARTORIUS AG 600
18.1.6.1 Business overview 600
18.1.6.2 Products & services offered 602
18.1.6.3 Recent developments 602
18.1.6.3.1 Expansions 602
18.1.7 BACHEM HOLDING AG 603
18.1.7.1 Business overview 603
18.1.7.2 Products & services offered 604
18.1.7.3 Recent developments 605
18.1.7.3.1 Deals 605
18.1.7.3.2 Expansions 606
18.1.8 BIOTAGE AB 607
18.1.8.1 Business overview 607
18.1.8.2 Products & services offered 607
18.1.8.3 Recent developments 608
18.1.8.3.1 Product launches 608
18.1.8.3.2 Deals 609
18.1.9 CEM CORPORATION 610
18.1.9.1 Business overview 610
18.1.9.2 Products & services offered 610
18.1.9.3 Recent developments 611
18.1.9.3.1 Product launches 611
18.1.10 BIO-SYNTHESIS, INC. 612
18.1.10.1 Business overview 612
18.1.10.2 Products & services offered 612
18.1.11 BIOSYNTH 614
18.1.11.1 Business overview 614
18.1.11.2 Products & services offered 614
18.1.11.3 Recent developments 615
18.1.11.3.1 Deals 615
18.1.11.3.2 Expansions 616
18.1.12 CSBIO 617
18.1.12.1 Business overview 617
18.1.12.2 Products & services offered 617
18.1.13 GL BIOCHEM (SHANGHAI) LTD. 618
18.1.13.1 Business overview 618
18.1.13.2 Products & services offered 618
18.1.14 MESA LABORATORIES, INC. 620
18.1.14.1 Business overview 620
18.1.14.2 Products & services offered 621
18.1.14.3 Recent developments 622
18.1.14.3.1 Product & service launches 622
18.1.14.3.2 Deals 623
18.1.15 DANAHER CORPORATION 624
18.1.15.1 Business overview 624
18.1.15.2 Products & services offered 625
18.1.15.3 Recent developments 627
18.1.15.3.1 Product launches 627
18.2 OTHER PLAYERS 628
18.2.1 CHEM-IMPEX INTERNATIONAL, INC. 628
18.2.2 ADVANCED CHEMTECH 629
18.2.3 MIMOTOPES PTY LTD. 630
18.2.4 IRIS BIOTECH GMBH 631
18.2.5 AAPPTEC, LLC 632
18.2.6 ENAMINE LTD. 634
18.2.7 INTAVIS PEPTIDE SERVICES GMBH 635
18.2.8 JPT PEPTIDE TECHNOLOGIES GMBH 636
18.2.9 INNOVAGEN AB 637
18.2.10 PEPTIDE PROTEIN RESEARCH LTD. 638
18.2.11 LIFETEIN LLC 639
18.2.12 CREATIVE PEPTIDES 640
18.2.13 GENEMED SYNTHESIS, INC. 641
18.2.14 CHINAPEPTIDES CO., LTD. 642
18.2.15 BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO. 643
19 RESEARCH METHODOLOGY 644
19.1 RESEARCH DATA 644
19.1.1 SECONDARY DATA 645
19.1.1.1 Key secondary sources 645
19.1.1.2 Key data from secondary research 645
19.1.2 PRIMARY DATA 646
19.1.2.1 Key primary participants 646
19.1.2.2 Breakdown of primary interviews 646
19.1.2.3 Key data from primary sources 646
19.2 MARKET SIZE ESTIMATION 647
19.2.1 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025 647
19.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up) 647
19.2.1.2 Approach 2: Primary research 649
19.2.1.2.1 Key industry insights 649
19.2.1.3 Approach 3: MnM repository analysis 649
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 650
19.3 MARKET GROWTH RATE PROJECTIONS 652
19.4 DATA TRIANGULATION 654
19.5 RESEARCH ASSUMPTIONS 655
19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 656
20 APPENDIX 657
20.1 DISCUSSION GUIDE 657
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 662
20.3 CUSTOMIZATION OPTIONS 664
20.4 RELATED REPORTS 664
20.5 AUTHOR DETAILS 665
圖表清單 List of Tables & Figures
TABLE 1 PEPTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS 61
TABLE 2 GLOBAL PEPTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 76
TABLE 3 LIST OF SOME LATE-STAGE PEPTIDE THERAPEUTICS 78
TABLE 4 PEPTIDE SYNTHESIS MARKET: IMPACT OF PORTER’S FIVE FORCES 83
TABLE 5 PEPTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM 89
TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT,
2023–2025 (USD) 91
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 (USD) 92
TABLE 8 IMPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND) 93
TABLE 9 IMPORT DATA FOR HS CODE 902720, 2021–2025 (UNITS) 94
TABLE 10 EXPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND) 95
TABLE 11 EXPORT DATA FOR HS CODE 902720, 2021–2025 (TONS) 95
TABLE 12 IMPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND) 96
TABLE 13 IMPORT DATA FOR HS CODE 841933, 2022–2025 (UNITS) 97
TABLE 14 EXPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND) 97
TABLE 15 EXPORT DATA FOR HS CODE 841933, 2022–2025 (TONS) 98
TABLE 16 PEPTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 99
TABLE 17 PEPTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2026 111
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET 115
TABLE 19 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS 116
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING TYPE (%) 125
TABLE 25 KEY BUYING CRITERIA, BY END USER 126
TABLE 26 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 130
TABLE 27 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 28 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 131
TABLE 29 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 30 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 31 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 32 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 133
TABLE 33 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 34 PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 35 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 36 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 37 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 38 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 39 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 40 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 41 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 139
TABLE 42 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 43 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 44 EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 45 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 46 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 47 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 142
TABLE 48 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 49 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 143
TABLE 50 PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 51 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 52 EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 53 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 54 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 55 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 56 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 57 PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 147
TABLE 58 AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 59 NORTH AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 60 EUROPE: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 61 ASIA PACIFIC: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 62 LATIN AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 63 MIDDLE EAST: AMINO ACID BUILDING BLOCKS MARKET, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 64 GCC COUNTRIES: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 65 RESINS MARKET, BY REGION, 2024–2031 (USD MILLION) 151
TABLE 66 NORTH AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 67 EUROPE: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 68 ASIA PACIFIC: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 69 LATIN AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 70 MIDDLE EAST: RESINS MARKET, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 71 GCC COUNTRIES: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 72 COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 73 NORTH AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 74 EUROPE: COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 75 ASIA PACIFIC: COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 76 LATIN AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 77 MIDDLE EAST: COUPLING REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 157
TABLE 78 GCC COUNTRIES: COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 79 PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 80 NORTH AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 81 EUROPE: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 82 ASIA PACIFIC: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 83 LATIN AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 84 MIDDLE EAST: PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 85 GCC COUNTRIES: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 86 LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 87 NORTH AMERICA: LABELING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 88 EUROPE: LABELING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 89 ASIA PACIFIC: LABELING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 90 LATIN AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 91 MIDDLE EAST: LABELING REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 92 GCC COUNTRIES: LABELING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 93 PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 165
TABLE 94 NORTH AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 95 EUROPE: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 96 ASIA PACIFIC: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 97 LATIN AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 98 MIDDLE EAST: PROTECTION & DEPROTECTION REAGENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 168
TABLE 99 GCC COUNTRIES: PROTECTION & DEPROTECTION REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 100 CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 101 NORTH AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 102 EUROPE: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 103 ASIA PACIFIC: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 104 LATIN AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 105 MIDDLE EAST: CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 171
TABLE 106 GCC COUNTRIES: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 107 OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 108 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 109 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 110 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 111 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 112 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 113 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 114 PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 175
TABLE 115 NORTH AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 116 EUROPE: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 117 ASIA PACIFIC: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 118 LATIN AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 119 MIDDLE EAST: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 120 GCC COUNTRIES: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 121 PEPTIDE SYNTHESIS INSTRUMENTS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS 179
TABLE 122 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 123 NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 124 EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 125 ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 126 LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 127 MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 128 GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 129 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 130 PEPTIDE SYNTHESIZERS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS 183
TABLE 131 PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 132 NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 133 EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 134 ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 135 LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 136 MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 186
TABLE 137 GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 138 PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 139 PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 187
TABLE 140 AUTOMATED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES 188
TABLE 141 AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 189
TABLE 142 NORTH AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 143 EUROPE: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 144 ASIA PACIFIC: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 145 LATIN AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 146 MIDDLE EAST: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 147 GCC COUNTRIES: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 148 MANUAL PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES 192
TABLE 149 MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 150 NORTH AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 151 EUROPE: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 152 ASIA PACIFIC: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 153 LATIN AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 154 MIDDLE EAST: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 155 GCC COUNTRIES: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 156 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES 196
TABLE 157 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 158 NORTH AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 159 EUROPE: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 160 ASIA PACIFIC: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 161 LATIN AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 162 MIDDLE EAST: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 199
TABLE 163 GCC COUNTRIES: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 164 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES 200
TABLE 165 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 200
TABLE 166 NORTH AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 167 EUROPE: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 168 ASIA PACIFIC: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 169 LATIN AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 170 MIDDLE EAST: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 171 GCC COUNTRIES: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 172 HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 173 NORTH AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 174 EUROPE: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 175 ASIA PACIFIC: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 176 LATIN AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 177 MIDDLE EAST: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 178 GCC COUNTRIES: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 179 OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 180 NORTH AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 181 EUROPE: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 182 ASIA PACIFIC: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 183 LATIN AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 184 MIDDLE EAST: OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION) 209
TABLE 185 GCC COUNTRIES: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 186 PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 210
TABLE 187 NORTH AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 188 EUROPE: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 189 ASIA PACIFIC: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 190 LATIN AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 191 MIDDLE EAST: PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 213
TABLE 192 GCC COUNTRIES: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 193 ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 214
TABLE 194 NORTH AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 195 EUROPE: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 196 ASIA PACIFIC: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 197 LATIN AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 198 MIDDLE EAST: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 216
TABLE 199 GCC COUNTRIES: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 200 LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 217
TABLE 201 NORTH AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 202 EUROPE: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 203 ASIA PACIFIC: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 204 LATIN AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 205 MIDDLE EAST: LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 220
TABLE 206 GCC COUNTRIES: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 207 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 208 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 209 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 210 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 211 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 212 MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 213 GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 214 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 225
TABLE 215 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 216 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 217 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 218 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 219 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 220 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 228
TABLE 221 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 222 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION) 229
TABLE 223 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 224 NORTH AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 225 EUROPE: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 226 ASIA PACIFIC: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 227 LATIN AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 228 MIDDLE EAST: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 229 GCC COUNTRIES: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 230 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 231 NORTH AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 232 EUROPE: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 233 ASIA PACIFIC: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 234 LATIN AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 235 MIDDLE EAST: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 236 GCC COUNTRIES: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 237 CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION) 237
TABLE 238 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 239 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 240 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 241 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 242 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 243 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 244 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 245 NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 246 EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 247 ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 248 LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 249 MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 243
TABLE 250 GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 251 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION) 243
TABLE 252 RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION) 244
TABLE 253 NORTH AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 254 EUROPE: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 255 ASIA PACIFIC: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 256 LATIN AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 257 MIDDLE EAST: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 258 GCC COUNTRIES: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 259 ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 248
TABLE 260 NORTH AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 261 EUROPE: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 262 ASIA PACIFIC: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 263 LATIN AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 264 MIDDLE EAST: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 250
TABLE 265 GCC COUNTRIES: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 266 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 252
TABLE 267 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 268 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 269 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 270 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 271 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 272 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 255
TABLE 273 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 274 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 256
TABLE 275 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 276 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 277 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 278 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 279 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS,
BY REGION, 2024–2031 (USD MILLION) 259
TABLE 280 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 281 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 260
TABLE 282 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 283 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 284 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 285 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 286 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 262
TABLE 287 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 288 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2024–2031 (USD MILLION) 263
TABLE 289 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 290 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 291 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 292 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 293 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 266
TABLE 294 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 295 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 296 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 297 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 298 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 299 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 300 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 301 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 302 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 271
TABLE 303 CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 272
TABLE 304 NORTH AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 305 EUROPE: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 306 ASIA PACIFIC: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 307 LATIN AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 308 MIDDLE EAST: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 274
TABLE 309 GCC COUNTRIES: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 310 PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 275
TABLE 311 NORTH AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 312 EUROPE: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 313 ASIA PACIFIC: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 314 LATIN AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 315 MIDDLE EAST: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 278
TABLE 316 GCC COUNTRIES: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 317 PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 279
TABLE 318 NORTH AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 319 EUROPE: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 320 ASIA PACIFIC: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 321 LATIN AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 322 MIDDLE EAST: PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 281
TABLE 323 GCC COUNTRIES: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 324 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 282
TABLE 325 NORTH AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 326 EUROPE: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 327 ASIA PACIFIC: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 328 LATIN AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 329 MIDDLE EAST: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 285
TABLE 330 GCC COUNTRIES: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 331 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 332 NORTH AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 333 EUROPE: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 334 ASIA PACIFIC: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 335 LATIN AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 336 MIDDLE EAST: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 288
TABLE 337 GCC COUNTRIES: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 338 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 290
TABLE 339 PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 291
TABLE 340 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 341 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 342 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 343 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 344 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 293
TABLE 345 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 346 PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 294
TABLE 347 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 348 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 349 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 350 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 351 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS,
BY REGION, 2024–2031 (USD MILLION) 297
TABLE 352 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 353 PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 298
TABLE 354 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 298
TABLE 355 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 356 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 357 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 358 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 300
TABLE 359 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 360 PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2024–2031 (USD MILLION) 301
TABLE 361 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 362 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 363 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 364 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 365 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 304
TABLE 366 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 367 PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 305
TABLE 368 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 369 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 370 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 371 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 372 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 307
TABLE 373 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 374 PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 309
TABLE 375 PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 310
TABLE 376 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 377 EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 378 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 379 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 380 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 312
TABLE 381 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 382 PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 313
TABLE 383 PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 314
TABLE 384 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 385 EUROPE: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 386 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 387 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 388 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 316
TABLE 389 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 390 PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 317
TABLE 391 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 392 EUROPE: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 393 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 394 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 395 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 320
TABLE 396 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 397 PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 321
TABLE 398 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 399 EUROPE: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 400 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 401 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 402 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 323
TABLE 403 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 404 PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 324
TABLE 405 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 325
TABLE 406 EUROPE: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 325
TABLE 407 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 408 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 409 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 327
TABLE 410 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 327
TABLE 411 PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 328
TABLE 412 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 328
TABLE 413 EUROPE: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 414 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 415 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 416 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 330
TABLE 417 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 418 PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 331
TABLE 419 PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY REGION, 2024–2031 (USD MILLION) 332
TABLE 420 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 421 EUROPE: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 422 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 423 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 424 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY REGION, 2024–2031 (USD MILLION) 334
TABLE 425 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 426 PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY REGION, 2024–2031 (USD MILLION) 335
TABLE 427 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS,
BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 428 EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 429 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS,
BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 430 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS,
BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 431 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS,
BY REGION, 2024–2031 (USD MILLION) 338
TABLE 432 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS,
BY COUNTRY, 2024–2031 (USD MILLION) 338
TABLE 433 PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS),
BY REGION, 2024–2031 (USD MILLION) 339
TABLE 434 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 435 EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 436 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 437 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 438 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY REGION, 2024–2031 (USD MILLION) 341
TABLE 439 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 440 PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY REGION, 2024–2031 (USD MILLION) 342
TABLE 441 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 343
TABLE 442 EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES,
BY COUNTRY, 2024–2031 (USD MILLION) 343
TABLE 443 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES,
BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 444 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES,
BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 445 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES,
BY REGION, 2024–2031 (USD MILLION) 345
TABLE 446 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION) 345
TABLE 447 PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY REGION, 2024–2031 (USD MILLION) 346
TABLE 448 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION) 346
TABLE 449 EUROPE: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION) 347
TABLE 450 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION) 347
TABLE 451 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION) 348
TABLE 452 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY REGION, 2024–2031 (USD MILLION) 348
TABLE 453 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION) 348
TABLE 454 PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 349
TABLE 455 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 350
TABLE 456 EUROPE: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 350
TABLE 457 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 351
TABLE 458 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 351
TABLE 459 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 352
TABLE 460 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 352
TABLE 461 PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 353
TABLE 462 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 353
TABLE 463 EUROPE: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 464 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 465 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 355
TABLE 466 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 355
TABLE 467 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 355
TABLE 468 PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 357
TABLE 469 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 470 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 359
TABLE 471 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 359
TABLE 472 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 359
TABLE 473 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 474 NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 475 NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 476 NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 361
TABLE 477 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 362
TABLE 478 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 479 NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 480 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 363
TABLE 481 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 363
TABLE 482 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 364
TABLE 483 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 364
TABLE 484 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 365
TABLE 485 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 365
TABLE 486 US: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 366
TABLE 487 US: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 366
TABLE 488 US: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 366
TABLE 489 US: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031
(USD MILLION) 367
TABLE 490 US: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031
(USD MILLION) 367
TABLE 491 US: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 492 US: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031
(USD MILLION) 368
TABLE 493 US: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 368
TABLE 494 US: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 495 US: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031
(USD MILLION) 369
TABLE 496 US: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031
(USD MILLION) 369
TABLE 497 US: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031
(USD MILLION) 370
TABLE 498 US: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 370
TABLE 499 US: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 371
TABLE 500 US: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 371
TABLE 501 US: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 372
TABLE 502 CANADA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 372
TABLE 503 CANADA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 373
TABLE 504 CANADA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 505 CANADA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031
(USD MILLION) 373
TABLE 506 CANADA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 507 CANADA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 508 CANADA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 374
TABLE 509 CANADA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 375
TABLE 510 CANADA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 511 CANADA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 512 CANADA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 376
TABLE 513 CANADA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 376
TABLE 514 CANADA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 377
TABLE 515 CANADA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 377
TABLE 516 CANADA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 377
TABLE 517 CANADA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 378
TABLE 518 EUROPE: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 378
TABLE 519 EUROPE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 379
TABLE 520 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 379
TABLE 521 EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 522 EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 523 EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 524 EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 525 EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 381
TABLE 526 EUROPE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 381
TABLE 527 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 528 EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 529 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 382
TABLE 530 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 383
TABLE 531 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 383
TABLE 532 EUROPE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 384
TABLE 533 EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 384
TABLE 534 EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 385
TABLE 535 GERMANY: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 385
TABLE 536 GERMANY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 386
TABLE 537 GERMANY: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 538 GERMANY: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 539 GERMANY: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 540 GERMANY: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 541 GERMANY: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 388
TABLE 542 GERMANY: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 388
TABLE 543 GERMANY: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 544 GERMANY: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 545 GERMANY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 390
TABLE 546 GERMANY: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 390
TABLE 547 GERMANY: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 391
TABLE 548 GERMANY: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031
(USD MILLION) 391
TABLE 549 GERMANY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 392
TABLE 550 GERMANY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 392
TABLE 551 UK: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 393
TABLE 552 UK: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 393
TABLE 553 UK: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 554 UK: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 555 UK: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 556 UK: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 557 UK: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 395
TABLE 558 UK: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 395
TABLE 559 UK: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 560 UK: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 561 UK: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 396
TABLE 562 UK: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 397
TABLE 563 UK: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 397
TABLE 564 UK: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 398
TABLE 565 UK: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 398
TABLE 566 UK: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 399
TABLE 567 FRANCE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 399
TABLE 568 FRANCE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 400
TABLE 569 FRANCE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 570 FRANCE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 571 FRANCE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 572 FRANCE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 573 FRANCE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 401
TABLE 574 FRANCE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 402
TABLE 575 FRANCE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 576 FRANCE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 577 FRANCE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 403
TABLE 578 FRANCE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 403
TABLE 579 FRANCE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 404
TABLE 580 FRANCE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 404
TABLE 581 FRANCE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 405
TABLE 582 FRANCE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 405
TABLE 583 ITALY: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 406
TABLE 584 ITALY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 406
TABLE 585 ITALY: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 586 ITALY: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 587 ITALY: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 588 ITALY: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 589 ITALY: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 408
TABLE 590 ITALY: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 408
TABLE 591 ITALY: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 592 ITALY: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 593 ITALY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 409
TABLE 594 ITALY: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 410
TABLE 595 ITALY: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 410
TABLE 596 ITALY: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 411
TABLE 597 ITALY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 411
TABLE 598 ITALY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 411
TABLE 599 SPAIN: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 412
TABLE 600 SPAIN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 412
TABLE 601 SPAIN: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 602 SPAIN: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 603 SPAIN: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 604 SPAIN: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 605 SPAIN: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 414
TABLE 606 SPAIN: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 415
TABLE 607 SPAIN: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 608 SPAIN: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 609 SPAIN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 416
TABLE 610 SPAIN: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 416
TABLE 611 SPAIN: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 417
TABLE 612 SPAIN: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031
USD MILLION) 417
TABLE 613 SPAIN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 418
TABLE 614 SPAIN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 418
TABLE 615 REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 419
TABLE 616 REST OF EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 419
TABLE 617 REST OF EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 618 REST OF EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 420
TABLE 619 REST OF EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 420
TABLE 620 REST OF EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 621 REST OF EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 421
TABLE 622 REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE,
2024–2031 (USD MILLION) 421
TABLE 623 REST OF EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 624 REST OF EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 625 REST OF EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 423
TABLE 626 REST OF EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 423
TABLE 627 REST OF EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 424
TABLE 628 REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 424
TABLE 629 REST OF EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 425
TABLE 630 REST OF EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 425
TABLE 631 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 427
TABLE 632 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 427
TABLE 633 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 427
TABLE 634 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 635 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 636 ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 637 ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 638 ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 430
TABLE 639 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 430
TABLE 640 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 641 ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 642 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 432
TABLE 643 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 432
TABLE 644 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 433
TABLE 645 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 433
TABLE 646 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 434
TABLE 647 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 434
TABLE 648 CHINA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 435
TABLE 649 CHINA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 435
TABLE 650 CHINA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 651 CHINA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 652 CHINA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 653 CHINA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 654 CHINA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 437
TABLE 655 CHINA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 438
TABLE 656 CHINA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 438
TABLE 657 CHINA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 438
TABLE 658 CHINA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 439
TABLE 659 CHINA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 439
TABLE 660 CHINA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 440
TABLE 661 CHINA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 440
TABLE 662 CHINA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 441
TABLE 663 CHINA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 441
TABLE 664 JAPAN: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 442
TABLE 665 JAPAN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 442
TABLE 666 JAPAN: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 667 JAPAN: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 668 JAPAN: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 669 JAPAN: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 670 JAPAN: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 444
TABLE 671 JAPAN: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 444
TABLE 672 JAPAN: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 673 JAPAN: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 674 JAPAN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 445
TABLE 675 JAPAN: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 446
TABLE 676 JAPAN: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 446
TABLE 677 JAPAN: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 447
TABLE 678 JAPAN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 447
TABLE 679 JAPAN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 448
TABLE 680 INDIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 448
TABLE 681 INDIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 449
TABLE 682 INDIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 683 INDIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 684 INDIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 685 INDIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 451
TABLE 686 INDIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 451
TABLE 687 INDIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 451
TABLE 688 INDIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 689 INDIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 690 INDIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 453
TABLE 691 INDIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 453
TABLE 692 INDIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 454
TABLE 693 INDIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 454
TABLE 694 INDIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 455
TABLE 695 INDIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 455
TABLE 696 SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 456
TABLE 697 SOUTH KOREA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 456
TABLE 698 SOUTH KOREA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 699 SOUTH KOREA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 457
TABLE 700 SOUTH KOREA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 457
TABLE 701 SOUTH KOREA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 458
TABLE 702 SOUTH KOREA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 458
TABLE 703 SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 458
TABLE 704 SOUTH KOREA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 705 SOUTH KOREA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 706 SOUTH KOREA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 460
TABLE 707 SOUTH KOREA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 460
TABLE 708 SOUTH KOREA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 461
TABLE 709 SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 461
TABLE 710 SOUTH KOREA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 462
TABLE 711 SOUTH KOREA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 462
TABLE 712 AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 463
TABLE 713 AUSTRALIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 463
TABLE 714 AUSTRALIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 463
TABLE 715 AUSTRALIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 716 AUSTRALIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 717 AUSTRALIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 718 AUSTRALIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 465
TABLE 719 AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 465
TABLE 720 AUSTRALIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 721 AUSTRALIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 722 AUSTRALIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 467
TABLE 723 AUSTRALIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 467
TABLE 724 AUSTRALIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 468
TABLE 725 AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 468
TABLE 726 AUSTRALIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 469
TABLE 727 AUSTRALIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 469
TABLE 728 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 470
TABLE 729 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 470
TABLE 730 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 470
TABLE 731 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 732 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 733 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 734 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 472
TABLE 735 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 472
TABLE 736 REST OF ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 737 REST OF ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 738 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 474
TABLE 739 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 474
TABLE 740 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 475
TABLE 741 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 475
TABLE 742 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 476
TABLE 743 REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 476
TABLE 744 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 477
TABLE 745 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 477
TABLE 746 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 477
TABLE 747 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 478
TABLE 748 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 478
TABLE 749 LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 479
TABLE 750 LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 479
TABLE 751 LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 480
TABLE 752 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE,
2024–2031 (USD MILLION) 480
TABLE 753 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 481
TABLE 754 LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 755 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 482
TABLE 756 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 482
TABLE 757 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 483
TABLE 758 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 483
TABLE 759 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 484
TABLE 760 LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 484
TABLE 761 BRAZIL: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 485
TABLE 762 BRAZIL: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 485
TABLE 763 BRAZIL: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 485
TABLE 764 BRAZIL: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 486
TABLE 765 BRAZIL: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 486
TABLE 766 BRAZIL: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 767 BRAZIL: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 487
TABLE 768 BRAZIL: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 487
TABLE 769 BRAZIL: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 488
TABLE 770 BRAZIL: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 488
TABLE 771 BRAZIL: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 488
TABLE 772 BRAZIL: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 489
TABLE 773 BRAZIL: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 489
TABLE 774 BRAZIL: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 490
TABLE 775 BRAZIL: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 490
TABLE 776 BRAZIL: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 491
TABLE 777 MEXICO: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 491
TABLE 778 MEXICO: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 492
TABLE 779 MEXICO: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 492
TABLE 780 MEXICO: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 781 MEXICO: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 782 MEXICO: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 783 MEXICO: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 494
TABLE 784 MEXICO: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 494
TABLE 785 MEXICO: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 495
TABLE 786 MEXICO: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 495
TABLE 787 MEXICO: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 495
TABLE 788 MEXICO: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 496
TABLE 789 MEXICO: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 496
TABLE 790 MEXICO: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 497
TABLE 791 MEXICO: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 497
TABLE 792 MEXICO: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 498
TABLE 793 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 498
TABLE 794 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 499
TABLE 795 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 499
TABLE 796 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 797 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 798 REST OF LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 501
TABLE 799 REST OF LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 501
TABLE 800 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 501
TABLE 801 REST OF LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 802 REST OF LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 803 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 503
TABLE 804 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 503
TABLE 805 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 504
TABLE 806 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 504
TABLE 807 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 505
TABLE 808 REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 505
TABLE 809 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 506
TABLE 810 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 506
TABLE 811 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 506
TABLE 812 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 507
TABLE 813 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 507
TABLE 814 MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 815 MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 816 MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 509
TABLE 817 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 509
TABLE 818 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 509
TABLE 819 MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 510
TABLE 820 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 510
TABLE 821 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 511
TABLE 822 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 511
TABLE 823 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 512
TABLE 824 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 512
TABLE 825 MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 513
TABLE 826 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 513
TABLE 827 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 514
TABLE 828 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 514
TABLE 829 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 514
TABLE 830 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 515
TABLE 831 GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 515
TABLE 832 GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 833 GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 516
TABLE 834 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 516
TABLE 835 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 517
TABLE 836 GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 517
TABLE 837 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 518
TABLE 838 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 518
TABLE 839 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 519
TABLE 840 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 519
TABLE 841 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 520
TABLE 842 GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 520
TABLE 843 SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 521
TABLE 844 SAUDI ARABIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 521
TABLE 845 SAUDI ARABIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 521
TABLE 846 SAUDI ARABIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 522
TABLE 847 SAUDI ARABIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 522
TABLE 848 SAUDI ARABIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 523
TABLE 849 SAUDI ARABIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 523
TABLE 850 SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 523
TABLE 851 SAUDI ARABIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 524
TABLE 852 SAUDI ARABIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 524
TABLE 853 SAUDI ARABIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 525
TABLE 854 SAUDI ARABIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 525
TABLE 855 SAUDI ARABIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 526
TABLE 856 SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 526
TABLE 857 SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 527
TABLE 858 SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 527
TABLE 859 UAE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 528
TABLE 860 UAE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 528
TABLE 861 UAE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 528
TABLE 862 UAE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 529
TABLE 863 UAE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 529
TABLE 864 UAE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 865 UAE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 530
TABLE 866 UAE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 530
TABLE 867 UAE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 531
TABLE 868 UAE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 531
TABLE 869 UAE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 531
TABLE 870 UAE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 532
TABLE 871 UAE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 532
TABLE 872 UAE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 533
TABLE 873 UAE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 533
TABLE 874 UAE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 533
TABLE 875 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 534
TABLE 876 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 534
TABLE 877 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 535
TABLE 878 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 535
TABLE 879 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 880 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 881 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 537
TABLE 882 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 537
TABLE 883 REST OF GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 884 REST OF GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 538
TABLE 885 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 538
TABLE 886 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 539
TABLE 887 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 539
TABLE 888 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 540
TABLE 889 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 540
TABLE 890 REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 541
TABLE 891 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 541
TABLE 892 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 542
TABLE 893 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 542
TABLE 894 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 542
TABLE 895 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 896 REST OF MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 897 REST OF MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 544
TABLE 898 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 544
TABLE 899 REST OF MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 900 REST OF MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 545
TABLE 901 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 545
TABLE 902 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 546
TABLE 903 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 546
TABLE 904 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 547
TABLE 905 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 547
TABLE 906 REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION) 548
TABLE 907 AFRICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 548
TABLE 908 AFRICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 549
TABLE 909 AFRICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 549
TABLE 910 AFRICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 550
TABLE 911 AFRICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 550
TABLE 912 AFRICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 551
TABLE 913 AFRICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 551
TABLE 914 AFRICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 551
TABLE 915 AFRICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 552
TABLE 916 AFRICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 552
TABLE 917 AFRICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 553
TABLE 918 AFRICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 553
TABLE 919 AFRICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 554
TABLE 920 AFRICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 554
TABLE 921 AFRICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 555
TABLE 922 AFRICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY MOLECULE, 2024–2031 (USD MILLION) 555
TABLE 923 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET 557
TABLE 924 PEPTIDE SYNTHESIS MARKET: DEGREE OF COMPETITION 560
TABLE 925 PEPTIDE SYNTHESIS MARKET: REGION FOOTPRINT 565
TABLE 926 PEPTIDE SYNTHESIS MARKET: OFFERING FOOTPRINT 566
TABLE 927 PEPTIDE SYNTHESIS MARKET: PRODUCT TYPE FOOTPRINT 567
TABLE 928 PEPTIDE SYNTHESIS MARKET: APPLICATION FOOTPRINT 568
TABLE 929 PEPTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 571
TABLE 930 PEPTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY OFFERING AND REGION 572
TABLE 931 PEPTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES, JANUARY 2023–
AUGUST 2026 575
TABLE 932 PEPTIDE SYNTHESIS MARKET: DEALS, JANUARY 2023–AUGUST 2026 576
TABLE 933 PEPTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026 576
TABLE 934 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 577
TABLE 935 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 578
TABLE 936 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–
AUGUST 2026 580
TABLE 937 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–AUGUST 2026 581
TABLE 938 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026 581
TABLE 939 MERCK KGAA: COMPANY OVERVIEW 583
TABLE 940 MERCK KGAA: PRODUCTS & SERVICES OFFERED 584
TABLE 941 MERCK KGAA: DEALS, JANUARY 2023–AUGUST 2026 586
TABLE 942 MERCK KGAA: EXPANSIONS, JANUARY 2023–AUGUST 2026 586
TABLE 943 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 588
TABLE 944 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 589
TABLE 945 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–
AUGUST 2026 590
TABLE 946 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW 592
TABLE 947 GENSCRIPT BIOTECH CORPORATION: PRODUCTS & SERVICES OFFERED 594
TABLE 948 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2023–AUGUST 2026 595
TABLE 949 KANEKA CORPORATION: COMPANY OVERVIEW 596
TABLE 950 KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED 597
TABLE 951 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–AUGUST 2026 599
TABLE 952 SARTORIUS AG: COMPANY OVERVIEW 600
TABLE 953 SARTORIUS AG: PRODUCTS & SERVICES OFFERED 602
TABLE 954 SARTORIUS AG: EXPANSIONS, JANUARY 2023–AUGUST 2026 602
TABLE 955 BACHEM HOLDING AG: COMPANY OVERVIEW 603
TABLE 956 BACHEM HOLDING AG: PRODUCTS & SERVICES OFFERED 604
TABLE 957 BACHEM HOLDING AG: DEALS, JANUARY 2023–AUGUST 2026 605
TABLE 958 BACHEM HOLDING AG: EXPANSIONS, JANUARY 2023–AUGUST 2026 606
TABLE 959 BIOTAGE AB: COMPANY OVERVIEW 607
TABLE 960 BIOTAGE AB: PRODUCTS & SERVICES OFFERED 607
TABLE 961 BIOTAGE AB: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026 608
TABLE 962 BIOTAGE AB: DEALS, JANUARY 2023–AUGUST 2026 609
TABLE 963 CEM CORPORATION: COMPANY OVERVIEW 610
TABLE 964 CEM CORPORATION: PRODUCTS & SERVICES OFFERED 610
TABLE 965 CEM CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026 611
TABLE 966 BIO-SYNTHESIS, INC.: COMPANY OVERVIEW 612
TABLE 967 BIO-SYNTHESIS, INC.: PRODUCTS & SERVICES OFFERED 612
TABLE 968 BIOSYNTH: COMPANY OVERVIEW 614
TABLE 969 BIOSYNTH: PRODUCTS & SERVICES OFFERED 614
TABLE 970 BIOSYNTH: DEALS, JANUARY 2023–AUGUST 2026 615
TABLE 971 BIOSYNTH: EXPANSIONS, JANUARY 2023–AUGUST 2026 616
TABLE 972 CSBIO: COMPANY OVERVIEW 617
TABLE 973 CSBIO: PRODUCTS & SERVICES OFFERED 617
TABLE 974 GL BIOCHEM (SHANGHAI) LTD.: COMPANY OVERVIEW 618
TABLE 975 GL BIOCHEM (SHANGHAI) LTD.: PRODUCTS & SERVICES OFFERED 618
TABLE 976 MESA LABORATORIES, INC.: COMPANY OVERVIEW 620
TABLE 977 MESA LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 621
TABLE 978 MESA LABORATORIES, INC.: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–AUGUST 2026 622
TABLE 979 MESA LABORATORIES, INC.: DEALS, JANUARY 2023–AUGUST 2026 623
TABLE 980 DANAHER CORPORATION: COMPANY OVERVIEW 624
TABLE 981 DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED 625
TABLE 982 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026 627
TABLE 983 CHEM-IMPEX INTERNATIONAL, INC.: COMPANY OVERVIEW 628
TABLE 984 ADVANCED CHEMTECH: COMPANY OVERVIEW 629
TABLE 985 MIMOTOPES PTY LTD.: COMPANY OVERVIEW 630
TABLE 986 IRIS BIOTECH GMBH: COMPANY OVERVIEW 631
TABLE 987 AAPPTEC, LLC: COMPANY OVERVIEW 632
TABLE 988 ENAMINE LTD.: COMPANY OVERVIEW 634
TABLE 989 INTAVIS PEPTIDE SERVICES GMBH: COMPANY OVERVIEW 635
TABLE 990 JPT PEPTIDE TECHNOLOGIES GMBH: COMPANY OVERVIEW 636
TABLE 991 INNOVAGEN AB: COMPANY OVERVIEW 637
TABLE 992 PEPTIDE PROTEIN RESEARCH LTD.: COMPANY OVERVIEW 638
TABLE 993 LIFETEIN LLC: COMPANY OVERVIEW 639
TABLE 994 CREATIVE PEPTIDES: COMPANY OVERVIEW 640
TABLE 995 GENEMED SYNTHESIS, INC.: COMPANY OVERVIEW 641
TABLE 996 CHINAPEPTIDES CO., LTD. (QYAOBIO): COMPANY OVERVIEW 642
TABLE 997 BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO.: COMPANY OVERVIEW 643
TABLE 998 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 653
TABLE 999 RISK ASSESSMENT 656
FIGURE 1 PEPTIDE SYNTHESIS MARKET SEGMENTATION & REGIONAL SCOPE 60
FIGURE 2 PEPTIDE SYNTHESIS MARKET: YEARS CONSIDERED 63
FIGURE 3 MARKET SCENARIO 65
FIGURE 4 GLOBAL PEPTIDE SYNTHESIS MARKET, 2024–2031 66
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2023–2026 67
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PEPTIDE SYNTHESIS MARKET 68
FIGURE 7 HIGH-GROWTH SEGMENTS IN PEPTIDE SYNTHESIS MARKET, 2026–2031 69
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PEPTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 70
FIGURE 9 SURGING DEMAND FOR GLP-1 AND OTHER PEPTIDE THERAPEUTICS TO DRIVE MARKET GROWTH 71
FIGURE 10 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF PEPTIDE SYNTHESIS MARKET IN NORTH AMERICA IN 2025 72
FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL PEPTIDE SYNTHESIS MARKET DURING FORECAST PERIOD 73
FIGURE 12 THERAPEUTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD 74
FIGURE 13 PEPTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
FIGURE 14 PEPTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
FIGURE 15 PEPTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS 87
FIGURE 16 PEPTIDE SYNTHESIS MARKET ECOSYSTEM 89
FIGURE 17 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TYPE, 2023–2025 (USD) 92
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD) 93
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
FIGURE 20 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS, 2015–2025 110
FIGURE 21 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET 114
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 125
FIGURE 23 KEY BUYING CRITERIA, BY END USER 125
FIGURE 24 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET SNAPSHOT 358
FIGURE 25 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET SNAPSHOT 426
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2021–2025 (USD MILLION) 558
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2025 559
FIGURE 28 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 563
FIGURE 29 PEPTIDE SYNTHESIS MARKET: COMPANY FOOTPRINT 564
FIGURE 30 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 570
FIGURE 31 EV/EBITDA OF KEY VENDORS 573
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 573
FIGURE 33 PEPTIDE SYNTHESIS MARKET: PRODUCT/SERVICE COMPARATIVE ANALYSIS 574
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 578
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2025) 584
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 589
FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2025) 593
FIGURE 38 KANEKA CORPORATION: COMPANY SNAPSHOT (2025) 597
FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT (2025) 601
FIGURE 40 BACHEM HOLDING AG: COMPANY SNAPSHOT (2025) 604
FIGURE 41 MESA LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 621
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 625
FIGURE 43 PEPTIDE SYNTHESIS MARKET: RESEARCH DESIGN 644
FIGURE 44 PEPTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES 646
FIGURE 45 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025 647
FIGURE 46 PEPTIDE SYNTHESIS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025) 648
FIGURE 47 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025) 648
FIGURE 48 PEPTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES 649
FIGURE 49 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 650
FIGURE 50 PEPTIDE SYNTHESIS MARKET: CAGR PROJECTIONS 652
FIGURE 51 PEPTIDE SYNTHESIS MARKET: DATA TRIANGULATION 654
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們